Gilead Wins FDA Approval for Trodelvy in Triple-Negative Breast Cancer
Gilead Sciences received FDA approval for Trodelvy in adult patients with triple-negative breast cancer (TNBC) for two indications, including first-line monotherapy. This expands the drug's label and could boost sales.
On June 25, 2026, Gilead Sciences (NASDAQ:GILD) announced that the U.S. Food and Drug Administration (FDA) approved Trodelvy (sacituzumab govitecan-hziy) for adult patients with triple-negative breast cancer (TNBC). The approval covers two new indications: Trodelvy as a single agent in the first-line setting and another indication not fully detailed in the source.
The Product
Trodelvy is an antibody-drug conjugate (ADC) targeting Trop-2, a protein commonly expressed in many solid tumors. TNBC is one of the most aggressive breast cancer subtypes with limited treatment options. Clinical trials demonstrated Trodelvy's efficacy in improving survival.
Pricing and Availability
Gilead has not disclosed pricing details yet. Trodelvy is expected to be available in the U.S. market soon, with other markets to follow.
Competition
Gilead faces competition from other TNBC therapies, such as Merck's (MRK) Keytruda in certain indications, as well as other ADCs. However, the first-line approval gives Trodelvy a competitive edge.
Potential Impact on the Company
The new approval is expected to boost Trodelvy's revenues, which is one of Gilead's key oncology assets. This could improve investor confidence in the company's ability to diversify beyond its HIV franchise.
Frequently Asked Questions
Found this useful? Share it